{"filings":[{"id":917958,"accession_number":"0001193125-26-261670","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2026-06-08T20:02:15+00:00","items":["5.07"],"status":"ready","headline":"CG Oncology stockholders elect two Class II directors, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Christina Rossi elected with 67,531,501 shares for (99.87% of votes cast); Victor Tong Jr. elected with 62,401,874 shares for.","Ernst & Young LLP ratified as independent auditor for FY2026 with 83,711,522 shares for (99.99% of votes cast).","Say-on-pay approved on advisory basis with 65,894,959 shares for (97.6% of votes cast).","Stockholders selected 1-year frequency for future advisory votes on executive compensation, with 66,962,791 shares for (99.2% of votes cast).","Company will hold say-on-pay votes annually until next required frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649806,"accession_number":"0001193125-26-237908","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2026-05-26T12:00:15+00:00","items":["5.02"],"status":"ready","headline":"CG Oncology President & COO Bellete to depart June 30; CEO Kuan becomes President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ambaw Bellete, President & COO, agreed to separation effective June 30, 2026; severance per existing employment agreement.","Arthur Kuan appointed as President in addition to his other roles, effective upon Bellete's departure.","Company has initiated a search for a Chief Commercial Officer.","No reason for departure given; transition appears orderly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97085,"accession_number":"0001193125-26-213440","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology Q1 net loss widens to $60.2M; BLA submission on track for Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $60.2M ($0.71 per share) vs $34.5M ($0.45) in Q1 2025.","Cash, cash equivalents & marketable securities $1.1B as of March 31, 2026; includes $391.4M from ATM sales.","BLA for cretostimogene in HR BCG-unresponsive NMIBC expected to complete in Q4 2026 after FDA alignment.","Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC anticipated 1H 2026.","Appointed Jim DeTore as CFO in April 2026; he brings 30+ years life sciences experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":1083000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97084,"accession_number":"0001193125-26-152044","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CG Oncology appoints Jim DeTore as CFO with $520K base and $5M equity","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim DeTore, age 61, appointed CFO effective April 13, 2026; previously served as interim principal financial officer since Nov 2025.","Initial annual base salary of $520,000 with target bonus of 45% of base salary.","Equity grants: $4M stock option (4-year vest, 25% one-year cliff) and $1M PSU award (vesting on first U.S. commercial sale and positive operating cash flow).","Severance includes 12 months base salary and COBRA for non-CIC terminations; 1.5x base salary and full vesting for CIC terminations.","DeTore reports to CEO and will work remotely from Boston area."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111577,"accession_number":"0001193125-26-079452","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology reports FY2025 net loss $161M; cash $903M provides runway to 1H 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $41.3M ($0.52/share) vs $31.8M ($0.46/share) in Q4 2024.","Full-year 2025 net loss $161.0M ($2.08/share) vs $88.0M ($1.41/share) in FY2024.","Cash, equivalents, and securities ~$903M as of Feb 26, 2026; funded into first half 2029.","PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC expected 1H 2026.","CORE-008 Cohort CX first combination results with gemcitabine in HR NMIBC expected 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":4040000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111576,"accession_number":"0001193125-26-011855","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CG Oncology ups ATM equity offering capacity by $300M to $550M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filing increases aggregate offering of common stock under Open Market Sale Agreement from $250M to $550M.","Previously sold 5,861,984 shares for gross proceeds of $250M under the agreement.","Amendment adds $300M in unregistered shares available for sale through Jefferies LLC.","Proceeds from future sales will be used for general corporate purposes as per prior prospectus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111575,"accession_number":"0001193125-26-008329","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CG Oncology Accelerates PIVOT-006 Phase 3 Data Readout to 1H 2026 and Reports Positive Cretostimogene Results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIVOT-006 topline data for cretostimogene in intermediate-risk NMIBC now expected in first half of 2026, nearly one year ahead of schedule.","BOND-003 Cohort P showed 95.7% HG-EFS at 3 months, 84.6% at 6 months, and 80.4% at 9 months; no Grade 3+ TRAEs or deaths.","CORE-008 Cohort A (BCG-naïve high-risk NMIBC with CIS) achieved 83.7% overall CR rate (79.2% original, 88.0% optimized administration).","No patients in BOND-003 or CORE-008 progressed to MIBC or underwent radical cystectomy; safety profile favorable.","IR NMIBC population in the US estimated over 50,000 patients; no FDA-approved therapies currently exist for adjuvant setting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128197,"accession_number":"0001193125-25-298160","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CG Oncology appoints Christina Rossi to board; director Simone Song resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christina Rossi appointed to Board as Class II director effective November 24, 2025.","Rossi receives $45K annual retainer and initial option award of 20,889 shares vesting over 3 years.","Simone Song resigned from Board and all committees effective November 22, 2025; no disagreement cited.","Song served on Audit Committee and chaired Compensation Committee; no replacement committees named.","Standard indemnification agreement entered with Rossi; no transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128196,"accession_number":"0001193125-25-283108","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CG Oncology CFO Robert Lapetina resigns; Jim DeTore named interim CFO effective Nov 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Lapetina resigned as interim principal financial and accounting officer, effective Nov 30, 2025.","Jim DeTore appointed interim principal financial and accounting officer, effective Nov 17, 2025, via consulting agreement with Monomoy Advisors.","DeTore to receive $32K for November (prorated) and $64K/month thereafter; initial term min 3 months, extendable 3 months.","DeTore previously CFO at Neurogastrx (2021-2025) and Bluebird Bio (2014-2016); independent consultant 2017-2021.","No family relationships or conflicts disclosed; DeTore eligible for standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128195,"accession_number":"0001193125-25-281672","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology Q3 net loss $43.8M ($0.57/share); initiates BLA for cretostimogene","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.8M ($0.57 per share) for Q3 2025 vs $20.4M ($0.30) in Q3 2024.","Cash, cash equivalents and marketable securities $680.3M, sufficient to fund operations into H1 2028.","Initiated rolling BLA submission to FDA for cretostimogene monotherapy in HR BCG-unresponsive NMIBC.","R&D expenses $27.9M (up 42% YoY), G&A $23.3M (up 168% YoY) driven by clinical trials and headcount.","Completed enrollment of Phase 3 PIVOT-006 trial in IR NMIBC 10 months ahead of schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":1718000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145005,"accession_number":"0001991792-25-000007","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CG Oncology presents updated corporate deck at Morgan Stanley conference; no specifics in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["The filing references a corporate presentation (Exhibit 99.1) provided at the Sept 9, 2025 Morgan Stanley conference.","Only a tagline and partial disclaimer header appear in the exhibit excerpt; no new clinical or financial data are visible.","No material changes or specific milestones were disclosed in the 8-K text itself.","Investors should seek the full presentation for any updated pipeline or financial information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145004,"accession_number":"0001991792-25-000004","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CG Oncology reports 41.8% 24-month CR in Phase 3 BOND-003 for cretostimogene","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["24-month CR rate of 41.8% (46/110) in BCG-unresponsive HR NMIBC; 12 additional CRs since April 2025 AUA.","90% of 12-month responders remained disease-free at 24 months; 96.6% free from progression to muscle-invasive disease.","No Grade 3+ TRAEs or deaths; median TRAE resolution 1 day; 97.3% completed all treatments.","Company plans BLA submission for cretostimogene in HR NMIBC unresponsive to BCG in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145003,"accession_number":"0000950170-25-105487","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology Q2 net loss $41.4M; jury kills ANI royalties; BOND-003 75.5% CR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.4M ($0.54/sh) vs $18.9M ($0.28/sh) year ago; R&D $31.3M, G&A $17.4M.","Cash $661.1M; runway into 1H'28; BLA submission for cretostimogene planned in Q4'25.","Jury unanimously ruled CG owes no future royalties to ANI, eliminating 5% commercial royalty.","BOND-003 Cohort C: 75.5% CR at any time; 12-mo CR 50.7%, 24-mo CR 42.3% (K-M); median DOR 28 mo.","CORE-008 Cohort CX (cretostimogene + gemcitabine) initiated in HR BCG-exposed NMIBC."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":52000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145002,"accession_number":"0000950170-25-095296","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Corleen Roche resigns effective Aug 5; Robert Lapetina named interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Corleen Roche resigns effective August 5, 2025.","Robert Lapetina, VP FP&A since May 2024, appointed interim principal financial and accounting officer.","Lapetina previously VP Finance and Controller at Immunome, Inc. and roles at Chubb, Teleflex, Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163383,"accession_number":"0000950170-25-083088","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CG Oncology stockholders elect three Class I directors, ratify EY as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Arthur Kuan, James J. Mulé, Leonard Post elected as Class I directors to serve until 2028 annual meeting.","Ratification of Ernst & Young as independent auditor for fiscal year ending Dec 31, 2025 was approved with 69.7M votes for, 7K against.","Broker non-votes of 8.45M shares on director elections; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163382,"accession_number":"0000950170-25-069825","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology Q1 net loss $34.5M; BLA submission on track for H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.5M ($0.45/share) vs $16.9M ($0.36) a year ago; R&D spend rose to $27.5M.","Cash $688.4M as of March 31, 2025; expected to fund operations into first half of 2028.","BOND-003 Cohort C: 75.5% CR at any time; 24-month CR rate 42.3% by K-M; 97.3% progression-free at 24 months.","Cohort P: 90.5% high-grade recurrence-free survival at 3 and 9 months in BCG-unresponsive Ta/T1 disease.","Anticipates starting BLA submission for cretostimogene in HR BCG-unresponsive NMIBC in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":52000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163381,"accession_number":"0000950170-25-058956","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CG Oncology reports 42.3% 24-month CR rate in BOND-003; 97.3% progression-free at 24 mo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BOND-003 Cohort C: 75.5% complete response (CR) at any time; 42.3% 24-month CR by K-M estimate.","Median duration of response 28 months; 58.3% of responders maintained CR at 24 months by K-M.","97.3% of patients free from progression to muscle-invasive bladder cancer at 24 months; 91.6% cystectomy-free.","No Grade 3+ treatment-related adverse events or deaths; median resolution of any TRAE was one day.","Cohort P (Ta/T1 without CIS): 90.5% high-grade recurrence-free survival at 3 and 9 months (n=24)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181310,"accession_number":"0000950170-25-046335","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology reports FY2024 net loss $88.0M; cash $742M; cretostimogene CR rate 75.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders $88.0M ($1.41/share) vs $67.8M ($15.65/share) in FY2023.","Cash and marketable securities $742.0M as of Dec 31, 2024; $238M oversubscribed equity offering extends runway to H1 2028.","Cretostimogene monotherapy achieved 75.5% complete response rate in BOND-003; median DoR exceeds 28 months.","R&D expenses $82.1M in FY2024 (up from $45.8M); G&A expenses $33.7M (up from $9.9M).","BLA submission for cretostimogene in HR BCG-unresponsive NMIBC anticipated H2 2025; CORE-008 topline data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181309,"accession_number":"0000950170-25-043497","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CG Oncology reports 75.5% complete response rate in Phase 3 bladder cancer trial; median DOR >28 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["83 of 110 patients (75.5%) achieved complete response at any time in BOND-003 for BCG-unresponsive NMIBC with CIS.","Median duration of response not reached but exceeds 28 months; 46% in CR at 12 months.","No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all expected treatments.","Translational data show no systemic exposure, eliminating need for close contact precautions post-treatment.","Data presented as late-breaking abstract at 40th Annual EAU Congress in Madrid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181308,"accession_number":"0000950170-25-004168","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CG Oncology enters amended employment agreements with CEO, President, and three other executives with enhanced severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Arthur Kuan and President/COO Ambaw Bellete: 1.5x salary + prorated bonus outside CIC; 2.0x salary + full bonus inside CIC.","COBRA premium payments for up to 18 months (CIC: 24 months) and 18-month equity acceleration (CIC: full vesting).","Bellete's June 2023 option of 432,311 shares gets full accelerated vesting after second anniversary on termination without cause outside CIC.","CMO Kasturi, CFO Roche, GC Patterson: 1.0x salary + 12-month COBRA outside CIC; 1.5x salary + 18-month COBRA inside CIC.","All agreements dated January 9, 2025; full text to be filed in 2024 Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198130,"accession_number":"0001193125-24-271116","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CG Oncology reports 74.5% CR rate in Phase 3 BOND-003; median DOR >27 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["74.5% (82/110) achieved complete response at any time (95% CI 65.4-82.4%).","Median duration of response not reached but exceeds 27 months; 63.5% probability of response at 12 months.","No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all treatments.","Progression-free survival at 12 months: 97.3%; no progression to muscle-invasive cancer.","Cystectomy-free survival at 12 months: 90.0%; 50% of reinduced patients converted to CR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198129,"accession_number":"0000950170-24-124636","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology Q3 net loss $20.4M; cash $540.7M, runway through 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.4M ($0.30 per share) vs $17.5M ($4.00) in Q3 2023.","Cash and securities $540.7M as of Sept 30, 2024; expects to fund operations through 2027.","R&D expenses $19.6M (up from $11.7M) driven by clinical trial and CMC costs.","G&A expenses $8.7M (up from $2.3M) due to personnel, professional fees, insurance.","Phase 3 BOND-003 cretostimogene results accepted as late-breaking abstract at SUO 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":683000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214258,"accession_number":"0000950170-24-093237","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology Q2 net loss $18.9M; cash $552.9M; positive CORE-001 combo data published in Nature Medicine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.9M ($0.28 EPS) vs $11.6M loss ($3.93 EPS) in Q2 2023; R&D spend $18.5M vs $9.8M YoY.","Cash, equivalents and marketable securities $552.9M as of June 30, 2024; runway expected through 2027.","CORE-001 (cretostimogene + pembrolizumab) achieved 54% complete response at 24 months; 100% progression-free survival at 24 months.","BOND-003 monotherapy showed 75.2% CR at any time (n=105); no Grade 3+ AEs or treatment-related discontinuations.","Expanded Access Program initiated first patient dosed in June; primary BOND-003 results expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":640000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233502,"accession_number":"0000950170-24-064309","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CG Oncology reports 54% CR at 24 months for cretostimogene combo in NMIBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 CORE-001 final results: 54% (19/35) complete response rate at 24 months in BCG-unresponsive HR-NMIBC with CIS.","Median duration of response exceeds 21 months; 95% of 12-month CR patients maintained CR for another 12 months.","Progression-free survival at 24 months was 100%; cystectomy-free survival at 24 months was 80% (100% for CR patients).","No synergistic toxicity observed; combination with pembrolizumab well tolerated.","FDA Breakthrough Therapy Designation granted in May 2023; company plans to incorporate findings into planned CORE-008 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233501,"accession_number":"0001193125-24-134805","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CG Oncology reports Q1 net loss $16.9M; cash $566.5M; cretostimogene 75.2% CR rate in BCG-unresponsive NMIBC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.9M ($0.36/sh) in Q1 2024 vs $12.4M ($3.22/sh) Q1 2023; R&D expense $17.2M (up from $7.8M).","Cash and securities $566.5M as of Mar 31, 2024, compared to $187.7M at Dec 31, 2023; runway sufficient through 2027.","Cretostimogene monotherapy achieved 75.2% complete response (79/105) in BOND-003 Phase 3 trial in BCG-unresponsive HR-NMIBC.","Completed oversubscribed $437M IPO in 2024; first Pt dosed in PIVOT-006 Phase 3; CORE-001 combo data to be presented at ASCO June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":529000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233500,"accession_number":"0001193125-24-130800","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CG Oncology Phase 3 BOND-003: cretostimogene achieves 75.2% complete response in high-risk NMIBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["75.2% complete response (79/105 patients; 95% CI: 65-83) at any time in BCG-unresponsive high-risk NMIBC.","29 patients maintained CR for ≥12 months; median duration of response not reached as of April 1, 2024.","92.4% cystectomy-free-survival; no CR patient had radical cystectomy or nodal/metastatic progression.","No Grade 3+ TRAEs; 1.8% serious TRAEs (Grade 2 cystitis, clot retention); no treatment discontinuations.","Topline data from fully enrolled Phase 3 BOND-003 expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251581,"accession_number":"0001193125-24-038506","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CG Oncology discloses 2023 executive bonuses in amended summary comp table","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Arthur Kuan awarded $189,000 performance bonus for 2023; total comp $3.93M.","COO Ambaw Bellete received $189,500 sign-on bonus plus $179,740 performance bonus; total $3.03M.","CMO Vijay Kasturi received $56,000 sign-on bonus plus $87,448 performance bonus; total $2.44M.","Bonuses omitted from Jan 2024 IPO prospectus; now reported in Item 5.02 filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251580,"accession_number":"0001193125-24-018715","cik":1991792,"company_name":"CG Oncology, Inc.","ticker":"CGON","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"CG Oncology completes IPO of 23M shares at $19.00, raising $437M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO closed on Jan 29, 2024: 23M shares (includes full exercise of underwriters' option for 3M additional shares) at $19.00/share.","Gross proceeds of $437.0 million before underwriting discounts and expenses.","Charter amended: authorized common stock increased to 700M shares; 70M shares of undesignated preferred stock authorized.","Charter establishes classified board with staggered three-year terms and limits stockholder actions by written consent.","Exclusive forum provisions for Securities Act claims in federal courts and Delaware Chancery for other claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5356536330.722368,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}